• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G/A 1 ea0218399-sc13ga1cent_biomx.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G/A

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No. 1)*

     

    BiomX Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    09090D400

    (CUSIP Number)

     

    Rodney Hodges

    Director
    c/o Geneva Trust Company (GTC) SA, Rue de l’Athénée 34

    1206 Genève, Switzerland
    Tel +41 22 789 1200

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)

     

      ☒ Rule 13d-1(c)

     

      ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 2 of 12 Pages

     

    1.

    NAMES OF REPORTING PERSON

     

    Rodney Hodges

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United Kingdom
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER
     

    0

    6. SHARED VOTING POWER
     
    560,267 
    7.

    SOLE DISPOSITIVE POWER
     

    0

    8. SHARED DISPOSITIVE POWER
     
    560,267 
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    560,267 

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.1%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    IN

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 3 of 12 Pages

     

    1. NAMES OF REPORTING PERSON

    POD Sàrl
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER


    560,267 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER


    560,267 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    560,267 

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.1%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    CO

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 4 of 12 Pages

     

    1. NAMES OF REPORTING PERSON

    Geneva Holding Company (GHC) SA
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER


    560,267 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER


    560,267 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    560,267 

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.1%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 5 of 12 Pages

     

    1. NAMES OF REPORTING PERSON

    Geneva Trust Company (GTC) SA
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Switzerland
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER


    560,267 

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER


    560,267 

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    560,267 

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.1%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 6 of 12 Pages

     

    1. NAMES OF REPORTING PERSON

    Centaurus Investments Limited
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    British Virgin Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER


    543,572

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER


    543,572

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    543,572

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.0%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    CUSIP No. 09090D400 13G/A Page 7 of 12 Pages

     

    1. NAMES OF REPORTING PERSON

    Telmina Limited
    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

    (a) ☐

    (b) ☐

    3. SEC USE ONLY
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    British Virgin Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER
     
    0
    6.

    SHARED VOTING POWER


    543,572

    7. SOLE DISPOSITIVE POWER
     
    0
    8.

    SHARED DISPOSITIVE POWER


    543,572

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    543,572

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)    

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.0%(1)

    12. TYPE OF REPORTING PERSON (see instructions)

    HC

     

    (1)Percentage is based on the 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, based on information contained in the Form 10-Q filed by the Issuer on August 14, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024.

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer

     

    BiomX Inc. (the “Issuer”)

       
    (b)

    Address of Issuer’s Principal Executive Offices

     

    22 Einstein Street, Floor 4

    Ness Ziona 7414003, Israel

     

    Item 2.

     

    (a) Name of Person Filing:

     

    This Statement of Beneficial Ownership on Schedule 13G, filed on October 28, 2024 (the “Statement”) is being filed by each of:

     

      (i) Telmina Limited;

     

      (ii) Centaurus Investments Limited;

     

      (iii) Geneva Holding Company (GHC) SA;

     

      (iv) Geneva Trust Company (GTC) SA;

     

      (v) POD Sàrl (all of which, above, are the “Reporting Entities”); and

     

      (vi) Rodney Hodges (the “Reporting Individual”),

     

    (each a “Reporting Person” and, collectively, the “Reporting Persons”). This Schedule 13G is being filed pursuant to a Joint Filing Agreement (the “Joint Filing Agreement”), a copy of which is filed herewith as Exhibit 99.1.

     

    Telmina Limited (“Telmina”) is an investment holding company that purchased the Shares (as defined below) of the Issuer that are the subject of this Statement of Beneficial Ownership on Schedule 13G. The entire share capital of Centaurus Investments Limited, the parent holding company of Telmina, is held by Geneva Trust Company (GTC) SA (as trustee of the VT Two Trust). Geneva Trust Company (GTC) SA, a subsidiary of Geneva Holding Company (GHC) SA, as trustee of VT Two Trust, has the authority to dispose of and exercise control over the disposal of the assets of the VT Two Trust. POD Sàrl, of which Mr. Rodney Hodges holds 100% of the share capital, wholly owns Geneva Holding Company (GHC) SA.

     

    The Reporting Individual does not make day-to-day voting or investment decisions with respect to the Shares held by the Reporting Entities and therefore disclaims beneficial ownership of them except to the extent of his pecuniary interest therein.

     

    (b)

    Address of Principal Business Office or, if None, Residence:

     

    The principal business office of each of the Reporting Persons are:

     

    Rodney Hodges, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    POD Sàrl, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Geneva Holding Company (GHC) SA, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Geneva Trust Company (GTC) SA, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Centaurus Investments Limited, Rue de l’Athénée 34, 1206 Genève, Switzerland 

    Telmina Limited, Rue de l’Athénée 34, 1206 Genève, Switzerland 

     

    (c)

    Citizenship:

     

    POD Sàrl, Geneva Holding Company (GHC) SA, and Geneva Trust Company (GTC) SA are organized under the laws of Switzerland and Centaurus Investments Limited and Telmina Limited are organized under the laws of the British Virgin Islands. The Reporting Individual is a citizen of the United Kingdom.

       
    (d)

    Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (the “Shares”)

       
    (e)

    CUSIP Number

     

    09090D400

     

    Page 8 of 12 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

    Item 4. Ownership.

     

    (a) (b) Number and percentage of Issuer Shares beneficially owned by each Reporting Person:

     

    Reporting Person  Number of Shares   Percentage of Class 
    Rodney Hodges   560,267    3.1%
    POD Sàrl   560,267    3.1%
    Geneva Holding Company (GHC) SA   560,267    3.1%
    Geneva Trust Company (GTC) SA   560,267    3.1%
    Centaurus Investments Limited   543,572    3.0%
    Telmina Limited   543,572    3.0%

     

    With respect to each of the Reporting Persons:

     

    (a) Number of shares as to which the Reporting Person has:  
         
      (i)

    Sole power to vote or to direct the vote: 

     

    Rodney Hodges: 0

    POD Sàrl: 0

    Geneva Holding Company (GHC) SA: 0

    Geneva Trust Company (GTC) SA: 0

    Centaurus Investments Limited: 0

    Telmina Limited: 0

     

    Page 9 of 12 Pages

     

     

      (ii)

    Shared power to vote or to direct the vote: 

     

    Rodney Hodges: 560,267 

    POD Sàrl: 560,267 

    Geneva Holding Company (GHC) SA: 560,267 

    Geneva Trust Company (GTC) SA: 560,267 

    Centaurus Investments Limited: 543,572

    Telmina Limited: 543,572

         
      (iii)

    Sole power to dispose or to direct the disposition of: 

     

    Rodney Hodges: 0

    POD Sàrl: 0

    Geneva Holding Company (GHC) SA: 0

    Geneva Trust Company (GTC) SA: 0

    Centaurus Investments Limited: 0

    Telmina Limited: 0

         
      (iv)

    Shared power to dispose or to direct the disposition of: 

     

    Rodney Hodges: 560,267 

    POD Sàrl: 560,267 

    Geneva Holding Company (GHC) SA: 560,267 

    Geneva Trust Company (GTC) SA: 560,267 

    Centaurus Investments Limited: 543,572

    Telmina Limited: 543,572

     

    Based on the Form 10-Q filed by the Issuer on August 14, 2024, there were 178,958,447 shares of Common Stock of the Issuer that were outstanding as of August 12, 2024, every ten of which were converted into one share of Common Stock pursuant to a reverse stock split that was effected on August 26, 2024, as detailed in the Form 8-K filed by the Issuer on August 16, 2024

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☒

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person. 

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. 

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Page 10 of 12 Pages

     

     

    Item 10. Certification.

     

    Each of the Reporting Persons hereby certifies as follows:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    RODNEY HODGES   POD SÀRL
             
    By: /s/ Rodney Hodges   By: /s/ Rodney Hodges
    Name:  Rodney Hodges   Name:  Rodney Hodges
    Date: October 28, 2024   Title: Authorized Signatory
          Date: October 28, 2024
             
    GENEVA HOLDING COMPANY (GHC) SA   GENEVA TRUST COMPANY (GTC) SA
         
    By: /s/ Rodney Hodges   By: /s/ Rodney Hodges
    Name:  Rodney Hodges   Name:  Rodney Hodges
    Title: Authorized Signatory   Title: Authorized Signatory
    Date: October 28, 2024   Date: October 28, 2024
             
    By: /s/ Tobias Reinmann   By: /s/ Tobias Reinmann
    Name:  Tobias Reinmann   Name:  Tobias Reinmann
    Title: Authorized Signatory   Title: Authorized Signatory
    Date: October 28, 2024   Date: October 28, 2024
             
    CENTAURUS INVESTMENTS LIMITED   TELMINA LIMITED  
             
    By: /s/ Rodney Hodges   By:   /s/ Rodney Hodges
    Name:  Rodney Hodges   Name:  Rodney Hodges
    Title: Authorized Signatory for and on behalf of Champel Directors Limited   Title: Authorized Signatory for and on behalf of Champel Directors Limited
    Date: October 28, 2024   Date:   October 28, 2024
             
    By: /s/ Tobias Reinmann   By: /s/ Tobias Reinmann
    Name:  Tobias Reinmann   Name:  Tobias Reinmann
    Title: Authorized Signatory for and on behalf of Florissant Global Limited   Title: Authorized Signatory for and on behalf of Florissant Global Limited
    Date: October 28, 2024   Date: October 28, 2024

     

    Page 11 of 12 Pages

     

     

    EXHIBIT INDEX

     

    99.1   Joint Filing Agreement, dated September 29, 2023, among Rodney Hodges, Geneva Holding Company (GHC) SA, Geneva Trust Company (GTC) SA, Centaurus Investments Limited, POD Sàrl and Telmina Limited (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by Centaurus Investments Limited on September 29, 2023).

     

     

    Page 12 of 12 Pages

     

    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by BiomX Inc.

      SCHEDULE 13G - BiomX Inc. (0001739174) (Subject)

      5/8/25 7:39:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B3 filed by BiomX Inc.

      424B3 - BiomX Inc. (0001739174) (Filer)

      4/24/25 8:47:36 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by BiomX Inc.

      EFFECT - BiomX Inc. (0001739174) (Filer)

      4/24/25 12:15:07 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

      NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that, as previously disclosed in its annual report on Form 10-K for the fiscal year ended December 31, 2024, which was filed with the Securities and Exchange Commission on March 25, 2025, the audit opinion contained a going concern qualification from the Company's independent registered public accounting firm. This announcement is being made solely to comply with the NYSE American Company Guide Sections 401(h) and 610(b), which require separate disclosure

      4/1/25 6:30:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/13/24 5:14:46 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      11/4/24 4:05:35 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by BiomX Inc.

      SC 13G/A - BiomX Inc. (0001739174) (Subject)

      10/28/24 4:01:32 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    See more
    • BiomX Announces the Appointment of Susan Blum to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

      4/18/24 8:00:00 AM ET
      $PHGE
      $PDLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Telum Therapeutics appoints Dr. Subhendu Basu as CEO

      Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

      3/19/24 5:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

      CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

      10/18/23 8:00:00 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by *Director by Deputization Flynn James E

      4 - BiomX Inc. (0001739174) (Issuer)

      4/23/25 5:49:02 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form 4 filed by Director Merril Gregory Louis

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:24:29 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: Chief Development Officer Bassan Merav was granted 79,597 shares (SEC Form 4)

      4/A - BiomX Inc. (0001739174) (Issuer)

      4/21/25 8:11:31 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PHGE
    Financials

    Live finance-specific insights

    See more
    • BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

      NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates. To participate in the conference call, please dial 1-877-407-0724 (U.S.) or +1 201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company's website at www.biomx.com. About BiomXBiomX is a clin

      5/8/25 7:00:11 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

      BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from placebo starting at week 7 and a difference greater than 40% by week 10Compared to placebo, BX211 also produced statistically significant1 improvements in both ulcer depth at week 13 (in patients with ulcer depth defined as bone at baseline) (p=0.048), and in reducing the expansion of ulcer area (p=0.017).BiomX is planning for a Phase 2/3 trial of BX211, pending U.S. Food and Drug Administration (FDA) feedback The Company will host a conference call and webcast today at 9:00 AM ET, followed by a

      3/31/25 6:30:57 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

      NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025. A press release reporting the results will be available in the Investors section of the Company's website at www.biomx.com. The Company intends to host a conference call and a live audio webcast on a later date to report fourth quarter and full year 2024 financial results, in conjunction with its expec

      3/19/25 12:35:31 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care